Бойцов с а артериальная гипертония
1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360, Issue 9349: 1903–13.
2. Ford ES, Ajani UA, Croft JB, et al. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000. The New England Journal of Medicine, 2007, 356; 237, p 2388–98.
3. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371; Issue 9623: 1513–8.
4. Vorobjeva OD, Denisenko MB, Elizarov VV, et al. The Demographic Yearbook of Russia. 2013: Statistical Handbook. Rosstat.— M. 2013; 543 pp. Russian (Воробьева О.Д., Денисенко М.Б., Елизаров В.В. и др. Демографический ежегодник России, Стат.сб. Росстат. M 2013; 543 c. https://www.gks.ru).
5. Kearney P, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22: 11–9.
6. Chow СK, Teo KK, Rangarajan S, et al. Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and LowIncome Countries. JAMA 2013; 310 (9): 959–68.
7. Falaschetti E, Chaudhury M, Mindell J, et al. Continued Improvement in Hypertension Management in England: Results From the Health Survey for England 2006. Hypertension 2009; 53: 480–6.
8. Kish L. Survey Sampling, New York: John Wiley and Sons, 1965.
9. Scientific Organizing Committee of the ESSE-RF. Epidemiology of cardiovascular diseases in different regions of Russia (ESSE-RF). The rationale for and design of the study. Preventive Medicine 2013; 6: 25–34. Russian (Научно-организационный комитет проекта ЭССЕ-РФ Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайн исследования. Профилактическая медицина 2013, 6: 25–34).
10. Shalnova SA, Conradi AO, Karpov YuA, et al. Cardiovascular mortality in 12 Russian federation regions — participants of the “Cardiovascular disease epidemiology in Russian regions” study. Russ J Cardiol 2012; 5 (97): 6–11. Russian (Шальнова С. А., Конради А. О., Карпов Ю. А. и др. Анализ смертности от сердечно-сосудистых заболеваний в 12 регионах Российской Федерации, участвующих в исследовании “Эпидемиология сердечно-сосудистых заболеваний в различных регионах России”. Российский кардиологический журнал 2012; 5 (97): 6–11).
11. Danaei G, Finucane MM, Lin JK. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5,4 million participants. Lancet 2011; 377, Issue 9765: 568–77.
12. Gu D, Reynolds K, Wu X, et al. Prevalence Awareness, Treatment, and Control of Hypertension in China. Hypertension 2002; 40: 920–7.
13. Grujić V, Dragnić N, Kvrgić S. Epidemiology of Hypertension in Serbia: Results of a National Survey. J Epidemiol 2012; 22 (3): 261–6.
14. Culter JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999– 2004. J Hypertension 2008; 818–27.
15. Cheng S, Xanthakis V, Sullivan LM, et al. Blood pressure tracking over the adult life course: patterns and correlates in the Framingham study. Hypertension 2012; 60: 1393–9.
16. Dorobantu M, Darabont RO, Badila E, et al. Prevalence, Awareness, Treatment, and Control of Hypertension in Romania: Results of the SEPHAR Study. Int. J Hypertens 2010; Article ID 970694, 6 pages, doi:10,4061/2010/970694.
17. Wright JD, Hughes JP, Ostchega Y, et al. Mean Systolic and Diastolic Blood Pressure in Adults Aged 18 and Over in the United States, 2001–2008. National Center Health Statistics Reports 2011; 35: 24.
18. Morenoff JD, House JS, Hansen BB, et al. Understanding social disparities in hypertension prevalence, awareness, treatment, and control: The role of neighborhood context. Social Science & Medicine 2007; 65, Issue 9: 1853–66.
19. Bielecka-Dabrowa A, Aronow W, Rysz J, Banach M. The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. Curr Cardiovasc Risk Rep 2011; 5: 174–9.
20. Cifkova R, Skodova Z, Bruthans J, et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. J Hypertension 2010; 28 (11): 2196–203.
21. Joffres M, Falaschetti E, Gillespie C. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open 2013; 3: e003423. doi:10.1136/bmjopen-2013–003423.
22. Oganov RG, Timofeeva TN, Koltunov IE, et al. Arterial hypertension epidemiology in Russia. The results of 2003–2010 Federal monitoring. Cardiovascular Therapy and Prevention 2011; 10 (1): 9–13. Russian (Оганов Р. Г., Тимофеева Т. Н., Колтунов И.Е. и др. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003–2010 гг. Кардиоваскулярная терапия и профилактика 2011; 10 (1): 9–13).
23. Reklaitiene R, Tamosiunas A, Virviciute D, et al. Trends in prevalence, awareness, treatment, and control of hypertension, and the risk of mortality among middle-aged Lithuanian urban population in 1983–2009 BMC Cardiovascular Disorders 2012, 12: 68 https://www.biomedcentral.com/1471–2261/12/68.
24. Robitaille С, Dai S, Waters C. Diagnosed hypertension in Canada: incidence, prevalence and associated mortality. CMAJ 2012; 184 (1): Е 49–56.
25. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557–62.
26. Boĭtsov SA, Filippov EV, Shal’nova SA, et al. Risk factors for noncommunicable diseases in the Ryazan Region (according to the data of the MERIDIAN-RU trial as the ESSE-RF pilot project). Preventive Medicine 2013; 6: 48–54. Russian (Бойцов С.А., Филиппов Е.В., Шальнова С.А. и др. Факторы риска неинфекционных заболеваний населения Рязанской области (по данным исследования МЕРИДИАН-РО как пилотного проекта исследования ЭССЕ-РФ). Профилактическая медицина 2013; 6: 48–54).
27. McAlister FA, Wilkins K, Joffres M, et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ 2011; 183 (9): 1007–13.
28. Meng XJ, Dong GH, Wang D, et al. Prevalence, awareness, treatment, control, and risk factors associated with hypertension in urban adults from 33 communities of China: the CHPSNE study. J Hypertens 2011; 29 — Issue 7: 1303–10.
29. Shalnova SA, Deev AD, Vihireva OV, et al. The prevalence of hypertension in Russia. Awareness, treatment and control. Profilaktika zabolevanij i ukreplenie zdorov’ja 2001; 2: 3–7. Russian (Шальнова С.А., Деев А. Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Ж Проф забол укреп здоровья 2001; 2: 3–7).
30. Kayima J, Wanyenze RK, Katamba A, et al. Hypertension awareness, treatment and control in Africa: a systematic review. BMC Cardiovascular Disorders 2013; 13: 54 https://www.biomedcentral.com/1471–2261/13/54.
31. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in Antihypertensive Medication Use and Blood Pressure Control Among United States adults With Hypertension: The National Health and Nutrition Examination Survey, 2001 to 2010. Circulation 2012; 126: 2105–14.
32. Wu X, Huxley R, Li L, et al. Prevalence awareness, treatment and control of hypertension in China: Data from the China National Nutrition and Health Survey 2002. Circulation 2008; 118: 2679–86.
33. Tocci G, Rosei EA, Ambrosioni E, et al. Blood pressure control in Italy: analysis of clinical data from 2005–2011 surveys on hypertension. J Hypertens 2012; 30 (6):1065–74.
34. Schäfer HH, Sudano I, Theus GR, et al. Target blood pressure attainment with antihypertensive therapy in Swiss primary care. Blood Pressure 2012; 21 (4): 211–9.
35. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206–52.
36. Llisterri JL, Rodriguez-Roca GC, Escobar C, et al. Treatment and blood pressure control in Spain during 2002–2010. J Hypertens 2012; 30, Issue 12: 2425–31.
37. Campbell N, Young ER, Drouin D, et al. A Framework for Discussion on How to Improve Prevention, Management, and Control of Hypertension in Canada. Canadian J Cardiology 2012; 28, Issue 3: 262–9.
38. McDonald M, Hertz RP, Unger AN, Lustik MB. Prevalence, Awareness, and Management of Hypertension, Dyslipidemia, and Diabetes Among United States Adults Aged 65 and Older. Journal of Gerontology: MEDICAL SCIENCES cite journal as: J Gerontol A Biol Sci Med Sci 2009; 64A (2): 256–63.
39. Mancia G, Ambrosioni E, Rosei EA, et al. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens 2005; 23: 1575–81.
40. Ezzati M, Oza S, Danaei G, Murray CJ. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation 2008; 117: 905–14.
41. Malyszko J, Muntner P, Rysz J. Blood Pressure Levels and Stroke: J-curve Phenomenon? Curr Hypertens Rep 2013; 15: 575–81.
42. Grassi G, Cifkova R, Laurent S, et al. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. Eur Heart J 2011; 32: 218–25.
Источник
1. Gottwald-Hostalek U., Sun N., Barho C., Hildemann S. Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine. Clin Pharmacol Drug Dev 2017;6 (l):9-18.
2. WHO. A global brief on hypertension. 2013. https://www.who.int/ cardiovascular_diseases /publications / global_brief_hyperten-sion/en/
3. Liu X., Xiang Z., Shi X. et al. The Risk Factors of High Blood Pressure among Young Adults in the Tujia-Nationality Settlement of China. Biomed Res Int. 2017;8315603: Epub 2017 Aug 28.
4. Nechaeva G. I., Loginova E. N., Tereschenko Yu. V., Shupina M. I. To the question of the treatment of young patients with arterial hypertension and overweight/obesity (according to the results of Camellia’s study) Trudnyj pacient 2010;8 (5):15-20. Russian (Нечаева Г. И., Логинова Е. Н., Терещенко Ю. В., Шупина М. И. К вопросу о лечении молодых пациентов с артериальной гипертензией и избыточной массой тела/ожирением (по результатам исследования Камелия). Трудный пациент 2010;8 (5):15-20).
5. Boytsov S. A., Balanova Y. A., Shalnova S. A. et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention 2014;13 (4):4-14. Russian (Бойцов С. А., Баланова Ю. А., Шальнова С. А. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика 2014;13 (4):4-14).
6. Zinchenko Yu. P., Pervichko E. I., Ostroumova O. D. Factors influencing the formation of burnout syndrome in patients with workplace hypertension. Rational Pharmacotherapy in Cardiology 2017;13 (2):213-220. Russian (Зинченко Ю. П., Первичко Е. И., Остроумова О. Д. Факторы, влияющие на формирование синдрома выгорания у пациентов с артериальной гипертензией на рабочем месте. Рациональная фармакотерапия в кардиологии 2017;13 (2):213-220).
7. Landsbergis P. A., Travis A., Schnall P. L. High Blood Pressure. Cardiovasc Prev 2013;20 (2):69-76.
8. Ostroumova O. D., Pervichko E. I., Zinchenko Yu. P. Psychological characteristics of patients with stress-induced arterial hypertension: a violation of the regulation of emotions as a central link of pathogenesis. Consilium Medicum 2016;10:98-105. Russian (Остроумова О. Д., Первичко Е. И., Зинченко Ю. П. Психологические особенности больных со стресс-индуцированной артериальной гипертонией: нарушение регуляции эмоций как центральное звено патогенеза. Consilium Medicum 2016;10:98-105).
9. Rathi P., Agarwal V., Kumar A. Sympathetic hyperactivity in children of hypertensive parents. Ann Neurosci 2013;20 (1):4-6.
10. Santi M., Simonetti B. G., Leoni-Foglia C. F. et al. Arterial hypertension in children. Curr Opin Cardiol 2015;30 (4):403-410.
11. Fisher J. P., Paton J. F. The sympathetic nervous system and blood pressure in humans: implications for hypertension. J Hum Hypertens 2012;26 (8):463-475.
12. Parati G., Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012;33 (9):1058-1066.
13. DiBona G. F., Kopp U. C. Neural control of renal function. Physiol Rev 1997;77:75-197.
14. Esler M. Looking at the sympathetic nervous system as a primary source. In: Zanchetti A., Robertson J. I. S., Birkenhager W. H., eds, Handbook of Hypertension: Hypertension Research in the Twentieth Century. Amsterdam: Elsevier 2004;81-103.
15. Krum H., Schlaich M. P., Whitbourn R. et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-1281.
16. Zhang Y., Moran A. E. Trends in the Prevalence, Awareness, Treatment, and Control of Hypertension Among Young Adults in the United States, 1999 to 2014. Hypertension 2017;70 (4):736-742.
17. Weber K. T., Brilla C. G., Janicki J. S. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993;27:341-348.
18. Kannel W. B. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J 1992;13 (Suppl D): 82-88.
19. Schlaich M. P., Kaye D. M., Lambert E. et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003;108:560-565.
20. Grigin V. A., Danilov N. M., Sagajdak O. V. et al. Methods of sympathetic activity evaluation in patients with systemic refractory hypertension. Sistemnye gipertenzii 2014;4:21-26. Russian (Григин В. А., Данилов Н. М., Сагайдак О. В. и др. Методы оценки симпатической активности у пациентов с рефрактерными к лечению системными гипертензиями. Системные гипертензии 2014;4:21-26).
21. Drukteinis J. S., Roman M.J., Fabsitz R. R. et al. Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults: the Strong Heart Study. Circulation 2007;115 (2):221-227.
22. Lorber R., Gidding S. S., Daviglus M. L. et al. Influence of systolic blood pressure and body mass index on left ventricular structure in healthy African-American and white young adults: the CARDIA study. J Am Coll Cardiol 2003;41:955-960.
23. Cuspidi C., Ciulla M., Zanchetti A. Hypertensive myocardial fibrosis. Nephrol Dial Transplant 2006;21 (1):20-23.
24. Diez M. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens 2007; 9:546-550.
25. Maceira A. M., Mohiaddin R. H. Cardiovascular magnetic resonance in systemic hypertension. J Cardiovasc Magn Reson 2012;14:28.
26. Lang R. M., Badano L. P., Mor-Avi V. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28 (1):1-39. e14.
27. Kang S.J., Lim H. S., Choi B.J. et al. Longitudinal strain and torsion assessed by two-dimensional speckle tracking correlate with the serum level of tissue inhibitor of matrix metalloproteinase-1, a marker of myocardial fibrosis, in patients with hypertension. J Am Soc Echocardiogr 2008;21:907-911.
28. Ishizu T., Seo Y., Kameda Y. et al. Left ventricular strain and transmural distribution of structural remodeling in hypertensive heart disease. Hypertension 2014;63 (3):500-506.
29. Oishi Y., Miyoshi H., Iuchi A. et al. Negative impact of cardiovascular risk factors on left atrial and left ventricular function related to aortic stiffness-new application of 2-dimensional speckle-tracking echocardiography. Circ J 2013;77:1490-1498.
30. de Simone G., Devereux R. B., Koren M.J. et al. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996;93:259-265.
31. Melenovsky V., Borlaug B. A., Rosen B. et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 2007;49:198-207.
32. Borlaug B. A., Lam C. S., Roger V. L. et al. Contractility and ventricular systolic stiffening in hypertensive heart disease. Insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009;54:410-418.
33. Morris D. A., Gailani M., Vaz Pérez A. et al. Left atrial systolic and diastolic dysfunction in heart failure with normal left ventricular ejection fraction. J Am Soc Echocardiogr 2011;24:651-662.
34. Alyohin M. N. Ultrasonic methods of myocardial strain assessment and their clinical significance. Moscow: Viadar 2012;88 p. Russian (Алехин М. Н. Ультразвуковые методы оценки деформации миокарда и их клиническое значение. Москва: Виадар 2012;88 с).
35. Boyd A. C., Lo Q Devine K. et al. Left atrial enlargement and reduced atrial compliance occurs early in Fabry cardiomyopathy. J Am Soc Echocardiogr 2013;26:1415-1423.
36. Kurt M., Wang J., Torre-Amione G., Nagueh S. F. Left atrial function in diastolic heart failure. Circ Cardiovasc Imaging 2009;2:10-15.
37. Cameli M., Lisi M., Focardi M. et al. Left atrial deformation analysis by speckle tracking echocardiography for prediction of cardiovascular outcomes. Am J Cardiol 2012;110 (2):264-269.
38. Her A. Y., Kim J. Y., Kim Y. H. et al. Left atrial strain assessed by speckle tracking imaging is related to new-onset atrial fibrillation after coronary artery bypass grafting. Can J Cardiol 2013;29 (3):377-383.
39. Kim D., Shim C. Y., Cho I.J. et al. Incremental value of left atrial global longitudinal strain for prediction of post stroke atrial fibrillation in patients with acute ischemic stroke. J Cardiovasc Ultrasound 2016;24 (1):20-27.
40. Hwang H.J., Choi E. Y., Rhee S.J. et al. Left atrial strain as predictor of successful outcomes in catheter ablation for atrial fibrillation: a two-dimensional myocardial imaging study. J Interv Card Electrophysiol 2009;26 (2):127-132.
41. Saha S. K., Anderson P. L., Caracciolo G. et al. Global left atrial strain correlates with CHADS2 risk score in patients with atrial fibrillation. J Am Soc Echocardiogr 2011;24 (5):506-512.
42. Costa C., Gonzalez-Alujas T., Valente F. et al. Left atrial strain: a new predictor of thrombotic risk and successful electrical cardioversion. Echo Res Pract 2016;3 (2):45-52.
43. Kadappu K. K., Abhayaratna K., Boyd A. et al. Independent echo-cardiographic markers of cardiovascular involvement in chronic kidney disease: the value of left atrial function and volume. J Am Soc Echocardiogr 2016;29 (4):359-367.
44. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-1357.
45. Dahlöf B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens 1992;5 (2):95-110.
46. Jennings G., Wong J. Regression of left ventricular hypertrophy in hypertension: changing patterns with successive meta-analyses. J Hypertens Suppl 1998;16 (6):S29-34.
47. Schmieder R. E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996;275 (19):1507-1513.
48. Schmieder R. E., Schlaich M. P., Klingbeil A. U., Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrology, dialysis, transplantation 1998; 13 (3):564-569.
49. Fagard R. H., Celis H., Thijs L., Wouters S. Regression of left ventricular mass by antihypertensive treatment. Hypertension 2009;54 (5):1084-1091.
50. Gosse P., Roudaut R., Herrero G., Dallocchio M. [beta]-Blockers vs. Angiotensin-Converting Enzyme Inhibitors in Hypertension: Effects on Left Ventricular Hypertrophy. J Cardiovasc Pharmacol 1990;16: S145 — S150.
51. de Teresa E., Gonzalez M., Camacho-Vazquez C., Tabuenca M.J. Effects of bisoprolol on left ventricular hypertrophy in essential hypertension. Cardiovasc Drugs Ther 1994;8 (6):837-843.
52. Ostroumova O. D., Kochetkov A. I., Lopukhina M. V. Comparative analysis of the efficacy of fixed-dose combinations of amlodipine/lisinopril and bisoprolol/hydrochlorthiazide in patients with essential arterial hypertension combined with obesity and overweight. Rational pharmacotherapy in cardiology 2017;13 (4):443-453. Russian (Остроумова О. Д., Кочетков А. И., Лопухина М. В. Сравнительный анализ эффективности фиксированных комбинаций амлодипин/лизиноприл и бисопролол/гидрохлор-тиазид у пациентов с гипертонической болезнью в сочетании с ожирением и избыточной массой тела. Рациональная фармакотерапия в кардиологии 2017;13 (4):443-453).
53. Yang J., Liu Y., Fan X. et al. A pathway and network review on beta-adrenoceptor signaling and beta blockers in cardiac remodeling. Heart Fail Rev 2014;19 (6):799-814.
54. Heineke J., Molkentin J. D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nature reviews. Mol Cell Biol 2006;7 (8):589-600.
55. MacDonnell S. M., Weisser-Thomas J., Kubo H. et al. CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes. Circ Res 2009;105 (4):316-325.
56. Preobrazhenskiy D. V., Sidorenko B. A., Pataraya S. A., Nekrasova N. I. Nebivolol — the third generation ß-adrenoblocker in the treatment of cardiovascular diseases. RMZh 2008;16 (5):277-284. Russian (Преображенский Д. В., Сидоренко Б. А., Патарая С. А., Некрасова Н. И. Небиволол — ß-адреноблокатор третьего поколения в лечении сердечно-сосудистых заболеваний. РМЖ 2008;16 (5):277-284).
57. Watts V. L., Sepulveda F. M., Cingolani O. H. et al. Anti-hypertrophic and anti-oxidant effect of beta3-adrenergic stimulation in myocytes requires differential neuronal NOS phosphorylation. J Mol Cell Cardiol 2013;62:8-17.
58. Gauthier C., Trochu J. N. Nebivolol: the first vasodilatory betablocker with a beta3-adrenergic agonist activity. Annales de cardiologie et d’angeiologie 2010;59 (3) 155-159.
59. Ozakca I., Arioglu-Inan E., Esfahani H. et al. Nebivolol prevents desensitization of ß-adrenoceptor signaling and induction of cardiac hypertrophy in response to isoprenaline beyond ß1-adrenoceptor blockage. Am J Physiol Heart Circ Physiol 2013;304 (9):H1267-H1276.
60. Xiang S., Zhang N., Yang Z. et al. Achievement of a target dose of bisoprolol may not be a preferred option for attenuating pressure overload-induced cardiac hypertrophy and fibrosis. Exper Ther Med 2016;12 (4):2027-2038.
61. Schlaich M. P., Kaye D. M., Lambert E. et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003;108 (5):560-565.
62. Fukui M., Goda A., Komamura K. et al. Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure. Heart and vessels 2016;31 (2):173-182.
63. Porter K. E., Turner N. A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009;123 (2):255-278.
64. Bujak M., Frangogiannis N. G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007;74 (2):184-195.
Источник
